John Reed

“Yeah, maybe just a big reason that we've had such a great start in psoriasis This is because of that trifecta of biologics-like efficacy, coupled with placebo-like safety, combined with the convenience of a once-a-day pill, and we think that'll play very well across all indications, including IBD, whereas Tom…”

“Yeah, maybe the preview on that, if you just look at our pipeline with molecules that have achieved POC, they're now in phase three, de-risked, and moving forward, there are 12 molecules that have those criteria in the pipeline today.”

“Yeah, and I think Jennifer covered the Sunrise program well, recognized that the approval with three months of – and that's being positioned for the intermediate risk non-muscle invasive bladder cancer, which is a very large population, is the most common genetic lesion in bladder cancer.”

“Now, first I would say that we really have become a more focused company in the last few years. Oncology, immunology, and neuroscience are really the foundational elements.”

“I want to start by discussing our first quarter performance, how we view the current environment, and why we remain confident in the long-term opportunity ahead of us.”